Controversies surrounding the drug — involving safety concerns, the drug’s modest efficacy and its high cost — continue to swirl.
Alzheimer’s drug Leqembi backed by FDA advisers for full approval
Controversies surrounding the drug — involving safety concerns, the drug’s modest efficacy and its high cost — continue to swirl.